MicroRNA-409-5p Inhibits GIST Tumorigenesis and Improves Imatinib Resistance by Targeting KDM4D Expression

Abstract

Objective

Gastrointestinal stromal tumors (GISTs) can rapidly proliferate through angiogenesis. Previous studies indicated the potential influence of microRNA on the progression of tumor immature angiogenesis. This study aimed to explore the specific mechanism by which microRNA-409-5p (miR-409-5p) contributes to GIST.

Methods

To identify genes potentially involved in the development and progression of GIST, the differences of miR-409-5p between tumors and adjacent tissues were first analyzed. Following this analysis, target genes were predicted. To further investigate the function of miRNA in GIST cells, two GIST cell lines (GIST-T1 and GIST882) were transfected with lentiviruses that stably expressed miR-409-5p and scrambled miRNA (negative control). Later, the cells were subjected to Western blotting and ELSA to determine any differences in angiogenesis-related genes.

Results

In GISTs, there was a decrease in the expression levels of miR-409-5p compared to the adjacent tissues. It was observed that the upregulation of miR-409-5p in GIST cell lines effectively inhibited the proteins hypoxia-inducible transcription factor 1β (HIF1β) and vascular endothelial growth factor A (VEGF-A). Further investigations revealed that miR-409-5p acted as an inhibitor of angiogenesis by binding to the 3′-UTR of Lysine-specific demethylase 4D (KDM4D) mRNA. Moreover, the combination of miR-409-5p with imatinib enhanced its inhibitory effect on angiogenesis.

Conclusion

This study demonstrated that the miRNA-409-5p/KDM4D/HIF1β/VEGF-A signaling pathway could serve as a novel target for the development of therapeutic strategies for the treatment of imatinib-resistance in GIST patients.

Keywords

microRNA-409-5p / KDM4D / gastrointestinal stromal tumor

References

[1] CorlessCL, BarnettCM, HeinrichMC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer, 2011, 11(12): 865-878

[2] MiettinenM, LasotaJ. Histopathology of gastrointestinal stromal tumor. J Surg Oncol, 2011, 104(8): 865-873

[3] JoensuuH, HohenbergerP, CorlessCL. Gastrointestinal stromal tumour. Lancet, 2013, 382(9896): 973-983

[4] ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012, 23(Suppl 7): vii49-55

[5] GoettschWG, BosSD, Breekveldt-PostmaN, et al.. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer, 2005, 41(18): 2868-2872

[6] RobertsPJ, EisenbergB. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer, 2002, 38(Suppl 5): S37-S38

[7] DemetriGD, von MehrenM, BlankeCD, et al.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7): 472-480

[8] BlankeCD, DemetriGD, von MehrenM, et al.. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol, 2008, 26(4): 620-625

[9] NishidaT, ShiraoK, SawakiA, et al.. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol, 2008, 13(3): 244-251

[10] JoensuuH, VehtariA, RiihimäkiJ, et al.. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. The Lancet Oncology, 2012, 13(3): 265-274

[11] BartelDP. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136(2): 215-233

[12] MattickJS. The genetic signatures of noncoding RNAs. PLoS Genet, 2009, 5(4): e1000459

[13] LuJ, GetzG, MiskaEA, et al.. MicroRNA expression profiles classify human cancers. Nature, 2005, 435(7043): 834-838

[14] JiJ, ShiJ, BudhuA, et al.. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med, 2009, 361(15): 1437-1447

[15] LingH, FabbriM, CalinGA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov, 2013, 12(11): 847-865

[16] BaderAG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet, 2012, 3: 120

[17] BaderAG, BrownD, StoudemireJ, LammersP. Developing therapeutic microRNAs for cancer. Gene Ther, 2011, 18(12): 1121-1126

[18] ChenL, ZhengJ, ZhangY, et al.. Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther, 2011, 19(8): 1521-1528

[19] HartmannP, ZhouZ, NatarelliL, et al.. Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4. Nat Commun, 2016, 7: 10521

[20] JeonYJ, KimT, ParkD, et al.. miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC. Nat Commun, 2018, 9(1): 5110

[21] JossonS, GururajanM, HuP, et al.. miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res, 2014, 20(17): 4636-4646

[22] PrakashR, JohnAA, SinghD. miR-409-5p negatively regulates Wnt/Beta catenin signaling pathway by targeting Lrp-8. J Cell Physiol, 2019, 234(12): 23507-23517

[23] YuH, XingH, HanW, et al.. MicroRNA-409-5p is upregulated in breast cancer and its downregulation inhibits cancer development through downstream target of RSU1. Tumour Biol, 2017, 39(5): 1010428317701647

[24] de RinaldisE, GazinskaP, MeraA, et al.. Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genomics, 2013, 14: 643

[25] WangG, YangX, LiC, et al.. PIK3R3 induces epithelial-to-mesenchymal transition and promotes metastasis in colorectal cancer. Mol Cancer Ther, 2014, 13(7): 1837-1847

[26] LuX, KangY. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res, 2010, 16(24): 5928-5935

[27] EswarappaSM, FoxPL. Antiangiogenic VEGF-Ax: A New Participant in Tumor Angiogenesis. Cancer Res, 2015, 75(14): 2765-2769

[28] GoelHL, MercurioAM. VEGF targets the tumour cell. Nat Rev Cancer, 2013, 13(12): 871-882

[29] SemenzaGL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene, 2010, 29(5): 625-634

[30] KumarMS, LuJ, MercerKL, et al.. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet, 2007, 39(5): 673-677

[31] GarzonR, MarcucciG, CroceCM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov, 2010, 9(10): 775-789

[32] LinS, GregoryRI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer, 2015, 15(6): 321-333

[33] BaiR, WengC, DongH, et al.. MicroRNA-409-3p suppresses colorectal cancer invasion and metastasis partly by targeting GAB1 expression. Int J Cancer, 2015, 137(10): 2310-2322

[34] HuF, LiH, LiuL, et al.. Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1beta/VEGFA signalling. Mol Cancer, 2018, 17(1): 107

[35] GebertLFR, MacRaeIJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol, 2019, 20(1): 21-37

[36] IsslerO, ChenA. Determining the role of microRNAs in psychiatric disorders. Nat Rev Neurosci, 2015, 16(4): 201-212

[37] KotaJ, ChivukulaRR, O’DonnellKA, et al.. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009, 137(6): 1005-1017

[38] JanssenHL, ReesinkHW, LawitzEJ, et al.. Treatment of HCV infection by targeting microRNA. N Engl J Med, 2013, 368(18): 1685-1694